BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+27.29%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.31B
AUM Growth
+$931M
(+17%)
Cap. Flow
-$8.53M
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
41.19%
Holding
231
New
21
Increased
88
Reduced
44
Closed
16
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$74M |
| 2 |
Charles River Laboratories
CRL
|
$42M |
| 3 |
Abbott
ABT
|
$19.7M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$18.1M |
| 5 |
Arvinas
ARVN
|
$17.9M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$108M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$84.8M |
| 3 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$84.7M |
| 4 |
Gilead Sciences
GILD
|
$35.3M |
| 5 |
Teladoc Health
TDOC
|
$32.6M |
Sector Composition
| 1 | Healthcare | 95.59% |
| 2 | Industrials | 0.45% |
| 3 | Technology | 0.42% |
| 4 | Communication Services | 0.09% |
| 5 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Nektar Therapeutics
NKTR
$543M
| $73.8M | 1.17% |
227,800
+16,274
| +8% | +$5.27M |
|
27
Illumina
ILMN
$15.2B
| $73.5M | 1.17% |
227,874
+14,737
| +7% | +$4.76M |
|
28
Boston Scientific
BSX
$159B
| $71.4M | 1.13% |
1,578,621
+158,633
| +11% | +$7.17M |
|
29
Exelixis
EXEL
$9.95B
| $69.3M | 1.1% |
3,930,700
+72,000
| +2% | +$1.27M |
|
30
Becton Dickinson
BDX
$54.3B
| $68.5M | 1.09% |
258,312
+52,464
| +25% | +$13.9M |
|
31
Cigna
CI
$80.2B
| $65.3M | 1.03% |
319,146
+79,852
| +33% | +$16.3M |
|
32
MacroGenics
MGNX
$121M
| $63.9M | 1.01% |
5,873,356
+747,792
| +15% | +$8.14M |
|
|
33
Teladoc Health
TDOC
$1.37B
| $62.8M | 1% |
750,045
-389,012
| -34% | -$32.6M |
|
34
Jazz Pharmaceuticals
JAZZ
$7.99B
| $56.9M | 0.9% |
381,303
+51,076
| +15% | +$7.62M |
|
35
Danaher
DHR
$143B
| $56.3M | 0.89% |
413,517
-5,832
| -1% | -$794K |
|
|
AKCA
36
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $53.6M | 0.85% |
3,162,643
+52,732
| +2% | +$893K |
|
|
37
Arvinas
ARVN
$580M
| $51M | 0.81% |
1,241,903
+435,500
| +54% | +$17.9M |
|
38
Edwards Lifesciences
EW
$47.7B
| $47.3M | 0.75% |
608,229
+24,933
| +4% | +$1.94M |
|
39
Centene
CNC
$14.8B
| $46.6M | 0.74% |
740,611
+47,697
| +7% | +$3M |
|
40
Baxter International
BAX
$12.1B
| $45.1M | 0.72% |
539,675
+184,107
| +52% | +$15.4M |
|
41
CRISPR Therapeutics
CRSP
$4.82B
| $44.5M | 0.71% |
730,462
-106,700
| -13% | -$6.5M |
|
|
42
Charles River Laboratories
CRL
$7.99B
| $43.2M | 0.69% |
283,098
+274,798
| +3,311% | +$42M |
|
43
Insmed
INSM
$30.3B
| $37.8M | 0.6% |
1,583,560
+392,080
| +33% | +$9.36M |
|
44
Voyager Therapeutics
VYGR
$204M
| $37.7M | 0.6% |
2,704,283
-400
| -0% | -$5.58K |
|
45
HCA Healthcare
HCA
$95.4B
| $37.3M | 0.59% |
252,628
+41,246
| +20% | +$6.1M |
|
46
Scholar Rock
SRRK
$3.3B
| $34.7M | 0.55% |
2,634,466
+437,366
| +20% | +$5.76M |
|
47
Stryker
SYK
$149B
| $33.9M | 0.54% |
161,255
-27,029
| -14% | -$5.67M |
|
48
Q32 Bio
QTTB
$20.9M
| $33.4M | 0.53% |
89,562
| – | – |
|
49
Sangamo Therapeutics
SGMO
$161M
| $32.2M | 0.51% |
3,850,000
+200,000
| +5% | +$1.67M |
|
50
Zimmer Biomet
ZBH
$20.8B
| $32.2M | 0.51% |
221,483
+72,779
| +49% | +$10.6M |
|